Home > News > Long-term Results of a Novel Minimally Invasive High-frequency Deep Sclerotomy Ab Interno Surgical Procedure for Glaucoma
Glaucoma
Read Time: 2 mins

Long-term Results of a Novel Minimally Invasive High-frequency Deep Sclerotomy Ab Interno Surgical Procedure for Glaucoma

Published Online: February 8th 2012 European Ophthalmic Review, 2012;6(1):17-9 DOI: http://doi.org/10.17925/EOR.2012.06.01.17
Authors: Bojan Pajic, Brigitte Pajic-Eggspuehler, Ivan Haefliger, Farhad Hafezi
Quick Links:
Abstract
Article
Article Information
Abstract:
Overview

High-frequency deep sclerotomy (HFDS) glaucoma surgery is a new ab interno procedure to lower the intraocular pressure in open-angle glaucoma. Using high-frequency energy, six small pockets are formed which significantly reduce the outflow resistance for aqueous humour. This article presents the impressive results of a long-term study about the HFDS glaucoma procedure and demonstrates its efficacy and safety. The operation technique and the devices used for a successful HFDS glaucoma intervention are described step by step.

Support: The publication of this article was funded by Oertli Instruments.

Keywords

Open-angle glaucoma, high-frequency deep sclerotomy (HFDS), abee® Glaucoma Tip, minimally invasive, intraocular pressure, surgical procedure, diathermy probe

Article:
Purpose

The aim of this study was to demonstrate the efficacy and safety of a new surgical procedure termed high-frequency deep sclerotomy ab interno (HFDS) (formerly STT) for the treatment of primary open-angle glaucoma and juvenile glaucoma.

Patients and Methods

Purpose

The aim of this study was to demonstrate the efficacy and safety of a new surgical procedure termed high-frequency deep sclerotomy ab interno (HFDS) (formerly STT) for the treatment of primary open-angle glaucoma and juvenile glaucoma.

Patients and Methods

The main inclusion criterion for this study was an insufficient response to medical treatment of intraocular pressure (IOP). Data were documented according to a prospective study protocol. Fifty-three HFDS procedures ab interno in 53 patients with primary open-angle glaucoma and five with juvenile glaucoma were carried out between 1 April 2002 and 31 July 2002.

High-frequency Diathermic Probe

The high-frequency diathermic probe (abee® Glaucoma Tip, Oertli Instrumente AG) consists of an inner platinum electrode, which is isolated from the outer coaxial electrode. The platinum probe tip is 1 mm in length, 0.3 mm high and 0.6 mm wide and is bent posteriorly at an angle of 15° (see Figures 1). The external diameter of the probe measures 0.9 mm. Modulated 500 kHz current generates a temperature of approximately 130°C at the tip of the probe. The set-up provides high-frequency power dissipation in the close vicinity of the tip. As a result, heating of tissue is locally very limited and is applied as a rotational ellipsoid.

Surgical Procedure

A clear corneal incision (1.2 mm wide) was placed in the temporal upper quadrant using a diamond knife. A second corneal incision was performed 120° apart from the first, followed by injection of Healon GV®. The high-frequency diathermic probe (abee Glaucoma Tip) was inserted through the temporal corneal incision. Visual inspection of the target zone (opposite the iridocorneal angle) was observed by a four-mirror gonioscopy lens. The high-frequency tip penetrates up to 1 mm nasally into the sclera through the trabecular meshwork and Schlemm’s canal (see Figure 2), forming a deep sclerotomy (i.e. ‘pockets’) 0.3 mm high and 0.6 mm wide (see Figure 3). This procedure was repeated four times within one quadrant. Healon GV was evacuated from the anterior chamber with bimanual irrigation/aspiration.

Results

The mean age of patients with open-angle glaucoma was 72.3 ± 12.3 years (range 15–92 years). Seventeen patients (32 %) were female and 36 patients (68 %) male. The mean age of patients with juvenile glaucoma was 9 ± 1.4 years (range 7–11 years). One patient (20 %) was female and four patients (80 %) male. In 25 cases (47.4 %) of open-angle glaucoma the right eye, and in 28 cases (52.6 %) the left eye, was treated. In three cases (60 %) of juvenile glaucoma the right eye, and in two cases (40 %) the left eye, was treated. Decimalised Snellen visual acuity was 0.7 ± 0.3 (range 0.1–1.0) for open-angle glaucoma and 0.58 ± 0.3 (range 0.1–0.8) for juvenile glaucoma, pre-operatively. For all patients the follow-up was 72 months.

Mean pre-operative IOP in the study population of 53 patients with primary open-angle glaucoma was 25.6 ± 2.3 mmHg (range 18–48 mmHg) and in the study population of five patients with juvenile glaucoma was 39.6 ± 2.3 mmHg (range 34–46 mmHg). Mean IOP after 72 months was 14.7 ± 1.8 mmHg (range 10–21 mmHg) for primary open-angle glaucoma and 13.2 ± 1.3 mmHg (range 12–15 mmHg) for juvenile glaucoma. The IOP drop for both groups was statistically highly significant (p<0.001) at all measured post-operative intervals (see Figures 4 and 5). Pressure reduction at any time of standardised follow-up was statistically significant compared with pre-operative data at a level of α<0.03 (Bonferroni-corrected). In the juvenile glaucoma group, with five patients there are not enough cases to get conclusive statistics but the results show the tendency.
At month 72 after surgery, 52.8 % of patients with open-angle glaucoma had an IOP <15 mmHg, 76 % had an IOP <18 mmHg and 79.2 % had an IOP <21 mmHg (see Figure 6); 80 % of patients with juvenile glaucoma had an IOP <15 mmHg and 100 % had an IOP <18 mmHg. After 72 months, 84.9 % achieved >20 % reduction in IOP and 77 % of treated patients with open-angle glaucoma achieved >30 % reduction of IOP.
After 72 months, 100 % of treated patients with juvenile glaucoma achieved >30 % reduction of IOP. The complete success rate, defined as an IOP lower than 21 mmHg without medication, was 79.2 % in the open-angle glaucoma group and 80 % in the juvenile glaucoma group at 72 months. The qualified success rate, defined as an IOP lower than 21 mmHg with medication, was 100 % for all patients at 72 months (see Figure 7). After 72 months, it was necessary to administer IOP-reducing medication in 11 eyes (20.8 %) in the open-angle glaucoma group (see Figure 8) and one eye (20 %) in the juvenile glaucoma group. There were no significant changes comparing the visual field for open-angle glaucoma, with mean defect (MD) 8.38 ± 2.44 and loss variance (LV) 27.7 ± 5.11 at baseline and MD 9.03 ± 2.45 and LV 28.2 ± 5.66 (p=0.29 for MD, p=0.37 for LV) at 72 months (see Figure 9), or for juvenile glaucoma, with MD 8.73 ± 3.12 and LV 28.2 ± 29.45 at baseline and MD 9.9 ± 1.97 and LV 21.3 ± 14.15 (p=0.56 for MD, p=0.72 for LV) at 72 months (see Figure 10).
For the five cases with juvenile glaucoma no side effects have been seen up to now. With more cases, complications could be visualised, such as the following described for the open-angle glaucoma group. Temporary IOP elevation higher than 21 mmHg was observed in 12 of 53 eyes (22.6 %). These patients responded well to pressure-reducing treatment with Timolol 0.5%, Dorzolamid or Bromonidin and medication could gradually be withdrawn in all of these patients. A single case of hypotension (1.9 %) was observed, that lasted for three days after surgery. Hyphaema was present in six cases (11.4 %), which disappeared within the first two weeks after surgery. One eye (1.9 %) exhibited transient fibrin formation. Fibrin was cleared within one day after frequent application of topical dexamethasone (see Figure 11).

Conclusions

HFDS (formerly STT) ab interno is a minimally invasive, safe and efficacious surgical technique for lowering IOP in open-angle glaucoma and juvenile glaucoma. Also, the technique avoids stimulation of episcleral and conjunctival tissues as in trabeculectomy and conventional non-penetrating surgery. In this study, diathermy was used to create four thalami and this corresponds to a resorption surface area of 2.4 mm2. The number of thalami chosen was arbitrary and seems to provide a sufficient long-term decrease in IOP as well as a low rate of post-operative complications. There is potential for a further IOP drop if six applications are made and we are currently investigating this. ■

Article Information:
Disclosure

The authors have no conflicts of interest to declare.

Correspondence

Bojan Pajic, Medical Director, Orasis Eye Clinic, Titlisstrasse 44, 5734 Reinach, Switzerland. E: bpajic@datacomm.ch

Received

2012-01-03T00:00:00

Further Resources

Share this Article
Related Content In Glaucoma
  • Copied to clipboard!
    accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72